Aug. 19 at 11:16 AM
$BNTX The positive topline results of the Phase 3 INterpath-001 study mark a historic milestone, as this is the world's first successful Phase 3 efficacy demonstration for a personalized mRNA cancer immunotherapy.
But from Merck and Moderna